Go To Global Site
Welcome to UCB in the United States



UCB Presents Number Needed to Treat Analysis for Bimekizumab in Moderate to Severe Plaque Psoriasis at AMCP Nexus

UCB today announced new data from a network meta-analysis (NMA) demonstrating that bimekizumab was associated with the lowest number needed to treat (NNT) to achieve Psoriasis Area and Severity Index (PASI) 90 and PASI 100 skin clearance levels compared with 12 other approved biologic therapies used for moderate to severe plaque psoriasis within 16 weeks. These results were presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2021, October 18-21. 



UCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older



New Two-Year Data Showed Bimekizumab Maintained High Levels of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis



UCB Welcomes Second Class of Virtual Interns

Tomorrow is National Intern Day 2021! We are pleased to continue our mission of investing in the next generation of the workforce by welcoming 32 student interns to our second virtual internship program.



Committed to Advancing Science and Delivering Value for Patients

With more than 90 years of innovation, at UCB, we come together every day to work, laser-focused, on a simple question: How will this create value for people living with severe diseases? Learn more about who we are at UCB.



Elevating the Voice of People with MG

This month in honor of Myasthenia Gravis (MG) Awareness Month, we have an opportunity to elevate the voices and needs of people with MG who remind us each day that our collective efforts can directly impact the everyday lives of MG patients – especially during times when immunocompromised individuals can face even more challenges than usual.



UCB+ as an Advocate for All

While many have felt the impact of the current environment, the members of UCB+, our employee resource group for the LGBTQ+ community and allies in UCB, recognize this time as an opportunity to lead. In commemoration of the 50th Atlanta Pride celebration, we’re pleased to share a little more about UCB+. 



UCB Engages Physicians to Meet Patients' Needs

Our recent launch of dynamic targeting in the U.S. is providing UCB a better grasp of physician needs, which can lead to better healthcare outcomes. This is a key building block in UCB’s digital transformation journey providing a proven blueprint and lessons learned to continue innovating now and in the future. This initiative was recognized as the Most Valuable Data and Insights Initiative at the Reuters Pharma Awards USA 2020. Read how UCB has improved efficiencies for our teams and helped evolve the field experience. The article was originally published by ZS.



Anita Moser and Erica Puntel Recognized as 2021 HBA Rising Stars

Congratulations to Anita Moser, Head of U.S. Neurology Assets and Optimization, and Erica Puntel, U.S. Neurology and Global Digital Business Transformation Communications Lead, for their recognition as Healthcare Businesswomen's Association (HBA) Rising Stars for 2021.



The IP PACT: Our Commitment to Putting Patients at the Heart of Our Approach to IP

UCB is proud to be one of 26 members launching the IP PACT and we invite you to learn more about the commitments we are making to ensure our approach to IP delivers value for society, patients, and UCB.